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Patients affected with Refsum disease (RD) have elevated levels of phytanic acid due to a deficiency of the peroxisomal
enzyme phytanoyl-CoA hydroxylase (PhyH). In most patients with RD, disease-causing mutations in the PHYH
gene have been identified, but, in a subset, no mutations could be found, indicating that the condition is genetically
heterogeneous. Linkage analysis of a few patients diagnosed with RD, but without mutations in PHYH, suggested
a second locus on chromosome 6q22-24. This region includes the PEX7 gene, which codes for the peroxin 7 receptor
protein required for peroxisomal import of proteins containing a peroxisomal targeting signal type 2. Mutations
in PEX7 normally cause rhizomelic chondrodysplasia punctata type 1, a severe peroxisomal disorder. Biochemical
analyses of the patients with RD revealed defects not only in phytanic acid a-oxidation but also in plasmalogen
synthesis and peroxisomal thiolase. Furthermore, we identified mutations in the PEX7 gene. Our data show that
mutations in the PEX7 gene may result in a broad clinical spectrum ranging from severe rhizomelic chondrodysplasia
punctata to relatively mild RD and that clinical diagnosis of conditions involving retinitis pigmentosa, ataxia, and
polyneuropathy may require a full screen of peroxisomal functions.
Refsum disease (RD [MIM 266500]) is a peroxisomal
disorder of branched-chain lipid metabolism, character-
ized by progressive adult retinitis pigmentosa, peripheral
neuropathy, anosmia, and cerebellar ataxia. Additional
symptoms include nerve deafness, skeletal dysplasia, ich-
thyosis, cataracts, and cardiac arrhythmias. The adoles-
cent onset of clinical symptoms is due to a gradual ac-
cumulation of phytanic acid (3,7,11,15-tetramethyl-
hexadecanoic acid), the only pathognomic biochemical
marker of RD (Wanders et al. 2001a, 2001b; Wierzbicki
et al. 2002). Because of the presence of a 3-methyl group,
phytanic acid cannot be degraded directly by b-oxida-
tion but instead undergoes one round of a-oxidation,
during which the terminal carboxyl group is removed
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to yield pristanic acid. The peroxisomal enzyme phy-
tanoyl-CoA hydroxylase (PhyH) catalyzes the first step
of a-oxidation, and mutations in the PHYH gene have
been identified in many patients with RD (Jansen et al.
1997, 2000; Mihalik et al. 1997; Mukherji et al. 2001).
Recent observations, however, pointed to genetic hetero-
geneity among patients with RD. First, in some patients
with RD, genetic analysis failed to identify mutations in
the PHYH gene, despite a marked deficiency in phytanic
acid a-oxidation (our unpublished data). Second, genetic
linkage studies revealed that not all patients with RD
could be linked to the PHYH locus at 10p13 (Wierzbicki
et al. 2000).
We conducted biochemical studies in fibroblasts from
two probands clinically diagnosed with RD but in whom
no mutations could be identified in the PHYH gene. Pro-
band 1 comes from a family of eight with three affected
sibs. He was born following an uneventful, full-term
pregnancy, became ataxic at age 12 years, and, on neu-
rological examination at age 19, had established retinitis
pigmentosa, with limited ocular fields, absence of night
blindness, and a normal electroretinogram (ERG). Other
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Table 1
Results of Biochemical Analyses
Subject
Phytanic Acid
a-Oxidation
(pmol/hr/mg)a
PhyH Activity
(nmol/hr/mg)b
Presence () or
Absence ()
of Peroxisomesc
Pristanic Acid
b-Oxidation
(pmol/hr/mg)d
Plasmalogen
Synthesis (ratio
Peroxisomal:
Microsomal)e
Control Individual 44 – 82 .10 – 1.00  675 – 1121 40 – 330
Patient with Classic RD 2 0  810 125.0
Patient with Zellweger 11 0  5 6.0
Patient with RCDP type 1 5 0  634 .9
Proband 1 5 .03  926 2.4
Proband 2 4 .04  NDf 3.0
a Phytanic acid a-oxidation was performed in intact cultured skin fibroblasts, as described elsewhere (Wanders and Van Roermund 1993).
b Phytanoyl-CoA activity was measured in skin fibroblast homogenates incubated for 30 min at 37C in a reaction mixture containing
25 mM Tris-HCl, 0.25 mM dithiothreitol, 3 mM ATP, 1.5 mM magnesium chloride, 0.2 mM coenzyme A (CoA), 0.25 mM ammonium
iron (II) sulphate, 1 mM 2-oxoglutarate, 2 mM ascorbate, 10 mM phytanoyl-CoA, final pH 7.5. After termination of the reaction by
addition of HCl, the product, 2-hydroxyphytanoyl-CoA, was hydrolyzed to form 2-hydroxyphytanic acid, which was measured by GC-
MS, essentially as described elsewhere (ten Brink et al. 1992).
c Presence of peroxisomes was ascertained by catalase immunofluorescence in cultured skin fibroblasts (Heikoop et al. 1991).
d Pristanic acid b-oxidation in intact cultured skin fibroblasts was performed as described elsewhere (Wanders et al. 1995).
e De novo plasmalogen synthesis was measured in intact cultured skin fibroblasts as described elsewhere (Schrakamp et al. 1988).
f Not determined.
features included anosmia, a short fifth metacarpal and
palmar ichthyosis, pes cavus, muscle weakness, and
nerve hypertrophy, which was confirmed by sural nerve
biopsy. His sister presented at age 20 years with post-
partum ataxia and numbness in her fingers and toes. She
had profound retinitis pigmentosa, an abnormal ERG,
anosmia, sensory and motor dysfunction with nerve hy-
pertrophy, and mild pes cavus. The third affected sib, a
brother, had mild retinitis pigmentosa and anosmia but
no other signs, on screening at age 24 years. Initial
plasma phytanic acid levels in the three individuals were
400 mM, 1,950 mM, and 372 mM (normal !30 mM),
respectively.
Proband 2 originates from a family comprising eight
sibs with two living affected members. Although born
with bilateral cataracts, she presented to a neurology
clinic, at age 20 years, with polyneuritis and onset of
ataxia at age 19 years. She had bilateral short fifth met-
acarpals and metatarsals, “arthritis” since age 25 years,
and mild retinitis pigmentosa. Her brother presented at
age 34 years with mild ataxia and mild retinitis pig-
mentosa but no night blindness, obvious anosmia, or
deafness. Neither patient had any episodes of ichthyosis
or signs of deafness. One other male sib died of supposed
“poliomyelitis” with symptoms of weakness and ataxia
at age 12 years. Their initial plasma phytanic acid levels
were 198 mM and 142 mM, respectively.
Patients were reviewed by specialized neurological units
and had full ophthalmological (Claridge et al. 1992),
smell test, audiological, balance, and electrophysiological
investigations performed. Skeletal changes were assessed
by a radiological survey (Plant et al. 1990). Dietary phy-
tanic acid intake was assessed by questionnaire (Brown
et al. 1993). Phytanic acid levels were measured in plasma
and adipose tissue biopsy specimens by use of standard
gas chromatographic techniques (Moser and Moser
1991). Sural nerve biopsy was performed for gross nerve
hypertrophy.
A deficiency of phytanic acid a-oxidation and of PhyH
activity was found in cultured skin fibroblasts of both
probands (table 1), which is in agreement with the clin-
ical diagnosis of RD. To identify the defective gene in
these patients, we performed multipoint linkage analysis
in the two families and found linkage to a region on
chromosome 6, which extended from D6S292 to D6S441,
with a peak LOD score of 1.92 between D6S314 and
D6S308, close to the loci for PEX7 and fatty acid–
binding protein 7 (fig. 1) (Wierzbicki et al. 2000). Pre-
vious studies have shown that mutations in the PEX7
gene cause rhizomelic chondrodysplasia punctata type 1
(RCDP type 1 [MIM 215100]) (Braverman et al. 1997;
Motley et al. 1997, 2002; Purdue et al. 1997; Braverman
et al. 2000). The PEX7 gene codes for the peroxin 7
protein, which has a function as a mobile receptor re-
quired for import into the peroxisome of proteins con-
taining a peroxisomal targeting signal type 2 (PTS2). In
RCDP type 1, a number of peroxisomal functions are
deficient, including PhyH activity, but peroxisomal bi-
ogenesis is not affected (Purdue et al. 1999). Hence, we
extended our biochemical analysis in the probands’ fi-
broblasts. A normal pristanic acid b-oxidation (table 1)
and a normal punctate pattern of catalase immunoflu-
orescence was found (results not shown), but plasmal-
ogen synthesis was deficient (table 1). The latter finding
has never been observed in RD but is characteristic of
patients who have RCDP type 1 (Hoefler et al. 1988),
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Figure 1 Multipoint linkage analysis of markers on chromosome
6, with approximate locations of known loci. With approval from the
ethics committee of each institution, 23 individuals, including 4 living
patients with a clinical RD phenotype, from the two families were
recruited through a specialized clinic, using diagnostic criteria specified
elsewhere (Wierzbicki et al. 2000). A panel of 11 fluorescein-labeled
dinucleotide repeat markers (Perkin Elmer) spanning 6q14-6qter
(GenLink home page) was amplified from extracted patient lympho-
cyte DNA (Puregene), by PCR, and typed on an ABI 310 analyzer
with GeneAmp software (Perkin Elmer). The data were analyzed using
the GENEHUNTER linkage analysis program (Kruglyak et al. 1996),
assuming complete penetrance for a recessive disorder and a mutation
rate of 105. The allele frequency for the RD trait was assumed to be
0.001 on the basis of the prevalence of RD of 106 in the United
Kingdom. Distances are in centimorgans from D6S242, which was
taken arbitrarily as zero. Apolipoprotein (a) p APO(A); estrogen re-
ceptor p E2R; peroxin 7/RCDP type 1 p PEX7; fatty acid binding
protein 7 p FABP7; oculodentodigital dysplasia p ODDD (MIM
164200).
Figure 2 Processing of PTS2 proteins into peroxisomes in con-
trol, classic RD, RCDP type 1, and probands 1 and 2. Lysates of
fibroblasts were subjected to western blotting, using antibodies AD-
HAPS (a), peroxisomal 3-oxoacyl-CoA thiolase (b), and PhyH (c).
Solid and open arrows indicate the position of the unprocessed and
mature forms, respectively. Immunoblot analyses were performed, as
described, for peroxisomal thiolase (Heikoop et al. 1990), ADHAPS
(de Vet et al. 1997), and PhyH with affinity-purified antibodies (Jansen
et al. 2000).
and it prompted us to further investigate possible ab-
errations in PTS2 protein import.
All of the currently known human PTS2 proteins un-
dergo processing upon import into the peroxisome. Per-
oxin 7 deficiency, however, leads to mislocalization and
cytosolic accumulation of unprocessed PhyH, alkyl-
dihydroxyacetonephosphate synthase (ADHAPS), and
peroxisomal 3-oxoacyl-CoA thiolase 1 (thiolase). The
difference in molecular weight between the unprocessed
precursor and mature proteins can be readily visualized
by a mobility shift on immunoblot (Heikoop et al. 1990;
Swinkels et al. 1991). As expected, ADHAPS was found
in its mature 67-kDa form in fibroblast homogenates
from both a normal control individual and a patient with
classic RD with mutations in the PHYH gene (fig. 2a).
In fibroblast homogenates from a patient with RCDP
type 1, the unprocessed 73-kDa form was found, which
is in agreement with the defective import of this protein
in patients with RCDP type 1 (Purdue et al. 1999). In
the two probands, both forms of the protein were de-
tected, suggesting a (partial) defect in PTS2 protein im-
port. Similar results were obtained when we performed
immunoblot analysis for peroxisomal thiolase (fig. 2b).
PhyH protein levels appeared to be much lower or absent
in the probands (fig. 2c), although, in fibroblast homo-
genates of proband 2, some protein could be detected
on longer exposures (not shown). The precursor of PhyH
could not be detected either in probands or in material
from patients with RCDP, which might indicate that it
is degraded more rapidly than precursors of ADHAPS
and peroxisomal thiolase.
When the results shown in figure 2 are examined
closely, it is clear that levels of processed thiolase and
PhyH are somewhat higher in proband 1 than in proband
2, whereas the opposite is found for ADHAPS. The under-
lying basis of this finding is not clear at present but may
well have to do with the nature of the two distinct (or
different) mutations found in the probands, each affecting
PTS2-protein import differently (see below).
Since the data described above suggested a deficiency
of peroxin 7, we performed mutation analysis of the
PEX7 gene, as described elsewhere (Motley et al. 2002),
and found that both patients were compound hetero-
zygotes for mutations in PEX7 (table 2). The Y40X
nonsense mutation, found in both probands, introduces
a premature stop codon in the N-terminal region of the
protein. This mutation has also been found in patients
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Table 2
Mutations in PEX7 in the Probands
Subject Nucleotide Change Amino Acid Change
Proband 1 120 CrG Y40X
12-18dupGTGCGGT Frameshift
Proband 2 120 CrG Y40X
40 ArC T14P
Figure 3 Functional complementation of PTS2-mediated peroxi-
somal protein import by PEX7 alleles. The three mutant PEX7 alleles
identified in the two probands were coexpressed with PTS2-tagged
GFP in cultured fibroblast of a patient with RCDP type 1, as described
elsewhere (Motley et al. 1997, 2002), to test their ability to restore
PTS2-mediated peroxisomal protein import. Expression of control
PEX7 resulted in punctate peroxisomal fluorescence (A), whereas the
Y40X allele resulted in cytosolic fluorescence (B). Expression of the
7-nt duplication (C) and the T14P allele (D) resulted in peroxisomal
and cytosolic fluorescence, respectively.
with classic RCDP type 1 with a severe clinical presen-
tation (Motley et al. 2002), which makes it unlikely to
be responsible for the mild clinical presentation observed
in the probands. In proband 1, a 7-nt duplication (12-
18dupGTGCGGT; table 2) was found on the second
allele, predicted to cause a frameshift leading to a pre-
mature stop codon at amino acid position 57. However,
the duplication occurs between two in-frame initiation
codons, which would suggest that use of the second ATG
may produce a protein that lacks the first 10 amino acids
but retains partial peroxin 7 transport function. The
second mutation in proband 2 was a T14P amino acid
substitution. Recent data from Braverman et al (2002)
would suggest that the T14P mutation lies in a stretch
of amino acids just before the first b strand. An amino
acid substitution in a b strand of peroxin 7 is thought
either to interfere with folding of the protein or to reduce
the affinity for its binding partners (Braverman et al.
2002). It remains to be established how the T14P mu-
tation interferes with the function of peroxin 7.
To investigate the effect of the mutations on the func-
tion of peroxin 7, we expressed the three patient PEX7
alleles, together with a PTS2-tagged GFP construct in
cultured skin fibroblast derived from a patient with
RCDP type 1 (fig. 3A). Expression of control PEX7 re-
sulted in a punctate fluorescence, indicating that PTS2-
protein import into the peroxisomes was restored. As
shown elsewhere (Motley et al. 2002), expression of the
Y40X allele does not restore PTS2-protein import, as
concluded from the diffuse, cytosolic fluorescence of
PTS2-GFP (fig. 3B). Expression of the 7-nt duplication
allele resulted in a punctate fluorescence, suggesting that
this allele, when overexpressed, can restore PTS2-protein
import (fig. 3C). Similar results with a relatively mild
PEX7 mutation have been shown elsewhere (Motley et
al. 2002). Restoration of import, however, could not be
observed upon expression of the T14P allele, with all
cells showing cytosolic fluorescence (fig. 3D).
To study the function of peroxin 7 endogenously, we
used immunofluorescence with peroxisomal thiolase an-
tibodies to investigate the subcellular localization of per-
oxisomal thiolase in cultured fibroblasts. Control fibro-
blasts showed a peroxisomal fluorescence, which was
absent in fibroblasts derived from a patient with RCDP
type 1, in whom a cytosolic labeling was observed (fig.
4). Likewise, in fibroblasts from proband 1, fluorescence
could be observed only in the cytosol, indicative of de-
fective PTS2-protein import into the peroxisomes in these
cells. The normal presence of peroxisomes and the import
of PTS1 proteins were established in all cell lines, using
immunofluorescence with catalase antibodies (fig. 4).
These experiments could not be carried out in cells from
proband 2, since no cultured fibroblasts were available
for study.
From these results, it appears that the 7-nt duplication
allele can restore PTS2-protein import when overex-
pressed, although, in an endogenous setting, peroxisomal
thiolase and other PTS2-proteins are predominantly pre-
sent in the cytosol in fibroblasts from proband 1, as
observed by immunofluorescence and western blotting.
In this context, it is surprising that the T14P allele does
not restore PTS2-protein import when overexpressed,
even though immunoblot results showed a mild import
defect. Further study is needed to explain this apparent
inconsistency.
As mentioned above, PEX7 is the gene involved in
RCDP type 1. It is interesting that the usual clinical
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Figure 4 Localization of peroxisomal thiolase in fibroblasts by immunofluorescence. Cultured fibroblasts derived from a control individual,
a patient with RCDP type 1, and proband 1 were stained, as described elsewhere, for catalase and peroxisomal thiolase (Heikoop et al. 1991).
No peroxisomal thiolase could be detected in the peroxisomes of proband 1, giving a cytosolic staining similar to that observed in the patient
with RCDP type 1.
presentation of patients affected with RCDP type 1 is
severe and quite different from RD, with patients show-
ing growth retardation, profound developmental delay,
cataracts, rhizomelia, dysostoses, and ichthyosis, with
death occurring within the first years of life. In addition,
a number of patients with a milder phenotypic variant
of RCDP type 1 have been described, but all followed
a classical presentation, with differences in degree of
cognitive impairment, longer life expectancy, and lack
of rhizomelia or chondrodysplasia (Poll-The et al. 1991;
Smeitink et al. 1992; Barth et al. 1996). These patients
all have been diagnosed with RCDP type 1 early in life,
whereas the patients we describe here were diagnosed
with classical RD in adulthood.
In conclusion, we have identified mutations in the
PEX7 gene in a subgroup of patients clinically diagnosed
with RD. In each patient, we found one mutation pre-
dicted to have a mild effect, which correlates with some
residual functional activity of peroxin 7 and, conse-
quently, also of the PTS2 proteins imported by peroxin
7, leading to a clinical phenotype normally associated
with RCDP instead of RD. This finding suggests that
mutations in the PEX7 gene can give rise to an over-
lapping clinical presentation ranging from RD to RCDP
similar to that of classical peroxisomal biogenesis dis-
orders, whose presentation ranges from severe Zellweger
syndrome to infantile Refsum disease (Gould et al. 2001).
Thus, investigation of patients with retinitis pigmentosa,
ataxia, and neuropathy may require a full screen of per-
oxisomal functions to identify the underlying genetic
cause of the disorder.
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